ArticleCell & bioscience2026
Integrative genomic profiling of iron homeostasis predicts clinical outcomes and identifies HAMP/hepcidin as a therapeutic target in colorectal cancer.
Article in Cell & bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Iron Metabolism in the Colorectal Tumor Microenvironment: Current Evidence and Clinical Implications.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundsColorectal cancer (CRC) is one of the most common and fatal cancers worldwide, often diagnosed at advanced stages. Iron homeostasis, a crucial metabolic pathway in cancer, significantly impacts tumor progression.
resultsThis study systematically investigated the function and significance of iron homeostasis-related genes (IHGs) in CRC, leading to the establishment of iron homeostasis-related molecular subtypes (IHMS) and a prognostic model based on their expression profiles of IHGs. Both IHMS and the model showed strong predictive accuracy for prognosis, clinical parameters, and response to immunotherapy. Patients classified as IHMS-B or exhibiting high model risk scores had poorer prognoses, while those categorized as IHMS-C or with low model risk scores were associated with more favorable outcomes and increased sensitivity to immunotherapy across multiple datasets. The model key gene HAMP (encoding hepcidin) was identified as a key oncogenic regulator that promotes CRC progression; elevated levels of HAMP/hepcidin were linked to peritoneal metastasis. Knocking out HAMP resulted in reduced tumor burden and inhibited proliferation and cancer stemness in both in vivo and in vitro models. Additionally, integration of in-house bulk-seq and tissue-array data further substantiated the clinical significance of HAMP/hepcidin and its association with immune landscapes.
conclusionsIn conclusion, both IHMS and the model serve as effective predictors for CRC prognosis and patient stratification. HAMP/hepcidin, a central regulator of iron homeostasis, plays a pivotal role in driving the progression and metastasis of CRC, underscoring the therapeutic potential of targeting the HAMP-mediated iron axis to improve clinical outcomes in CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.